Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients
- PMID: 17504997
- DOI: 10.1158/1078-0432.CCR-07-0050
Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients
Abstract
Purpose: A decrease in the frequency and activation state of dendritic cells in the sentinel lymph node (SLN) has been observed in early stages of melanoma development. This may hinder the generation of effective antitumor T-cell responses and increase the likelihood of metastatic spread. Immunopotentiation of the melanoma SLN may therefore be a valuable adjuvant treatment option. One way to achieve this is through the use of bacterially derived unmethylated cytosine-phosphate-guanine (CpG) DNA sequences that bind Toll-like receptor 9 and activate plasmacytoid dendritic cells (PDC). CpG-activated PDC, in turn, release IFN alpha and may thus boost T-cell and natural killer cell responses as well as activate conventional myeloid dendritic cells (MDC).
Experimental design: We studied the effects of preoperative local administration of the CpG B-type oligodeoxynucleotide (ODN) PF-3512676 (formerly known as CPG 7909) on dendritic cell and T-cell subsets in the SLN of 23 stage I to III melanoma patients, randomized to receive intradermal injections of either PF-3512676 or saline (NaCl 0.9%).
Results: PF-3512676 administration resulted in bulkier SLN, higher yields of isolated SLN leukocytes, and activation of BDCA-2(+)CD123(+) PDC as well as of CD1a(+) MDC. In addition, PF-3512676 administration was associated with the presence of a newly identified CD11c(hi)CD123(+)CD83(+)TRAIL(+) mature SLN-MDC subset, an increased release of a variety of inflammatory cytokines, and lower frequencies of CD4(+)CD25(hi)CTLA-4(+)FoxP3(+) regulatory T cells in the SLN.
Conclusions: These findings point to the possible utility of the conditioning of SLN by PF-3512676 as an adjuvant immunotherapeutic modality for early-stage melanoma.
Similar articles
-
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711. Clin Cancer Res. 2008. PMID: 18628468 Clinical Trial.
-
Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.Clin Cancer Res. 2006 May 1;12(9):2826-33. doi: 10.1158/1078-0432.CCR-05-2431. Clin Cancer Res. 2006. PMID: 16675577 Clinical Trial.
-
Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.Cancer Immunol Immunother. 2016 Apr;65(4):405-15. doi: 10.1007/s00262-016-1811-z. Epub 2016 Mar 2. Cancer Immunol Immunother. 2016. PMID: 26935057 Free PMC article. Clinical Trial.
-
Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option.Immunobiology. 2006;211(6-8):651-61. doi: 10.1016/j.imbio.2006.06.009. Epub 2006 Jul 28. Immunobiology. 2006. PMID: 16920504 Review.
-
[The latest diagnostical methods and therapy in melanoma].Przegl Lek. 2006;63(8):674-80. Przegl Lek. 2006. PMID: 17441381 Review. Polish.
Cited by
-
Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift.Front Immunol. 2024 Jan 3;14:1227648. doi: 10.3389/fimmu.2023.1227648. eCollection 2023. Front Immunol. 2024. PMID: 38239354 Free PMC article.
-
In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.Oncoimmunology. 2014 Jul 3;3(7):e946360. doi: 10.4161/21624011.2014.946360. eCollection 2014. Oncoimmunology. 2014. PMID: 25610730 Free PMC article.
-
Radiation and Anti-Cancer Vaccines: A Winning Combination.Vaccines (Basel). 2018 Jan 30;6(1):9. doi: 10.3390/vaccines6010009. Vaccines (Basel). 2018. PMID: 29385680 Free PMC article. Review.
-
Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer.Hum Gene Ther. 2009 Apr;20(4):303-13. doi: 10.1089/hum.2008.124. Hum Gene Ther. 2009. PMID: 19272013 Free PMC article.
-
Regulatory T cells and treatment of cancer.Curr Opin Immunol. 2008 Apr;20(2):241-6. doi: 10.1016/j.coi.2008.04.008. Epub 2008 May 27. Curr Opin Immunol. 2008. PMID: 18508251 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials